Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01233297
Other study ID # 2010-018592-16
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date November 2010
Est. completion date July 2024

Study information

Verified date February 2024
Source Copenhagen Studies on Asthma in Childhood
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Copsac has discovered that asthmatic exacerbations are as closely linked to bacterial as to viral infection. The current study will examine whether treatment of asthmatic exacerbations with macrolide antibiotics - in the abscence of clear clinical bacterial infection which would in any case precipitate antibiotic treatment - has an effect on either the particular episode, or subsequently. Macrolide antibiotics are chosen for ease of administration ensuring high compliance, antibiotic appropriacy, and anti-inflammatory properties.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 70
Est. completion date July 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 1 Year to 3 Years
Eligibility Inclusion Criteria: - Participation in the COPSAC2010 cohort - recurrent wheeze - and others Exclusion Criteria: - Macrolide allergy - Heart, liver or kidney disease. - and others

Study Design


Related Conditions & MeSH terms

  • Asthma
  • Childhood Asthma With Acute Exacerbation

Intervention

Drug:
Azithromycin
10 mg/kg peroral for 3 consecutive days
Other:
Placebo mixture
Placebo mixture containing no active substance.

Locations

Country Name City State
Denmark Copsac, DBAC Gentofte Copenhagen
Denmark Copsac, Næstved Hospital, Pediatric Department Naestved

Sponsors (1)

Lead Sponsor Collaborator
Copenhagen Studies on Asthma in Childhood

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Symptom scoring 1 to 3 years of age
Primary Duration in days of each asthmatic episode from randomisation start 1 to 3 years of age
Secondary need for PO steroids during the episode 1 to 3 years of age
Secondary beta-agonist use during the asthmatic episode 1 to 3 years of age
Secondary time lapse until the next asthmatic episode 1 to 3 years of age
Secondary MD assessment of the episode 1 to 3 years of age
Secondary Family's assessment of the episode 1 to 3 years of age
Secondary Asthma related health and economic assessment 1 to 3 years of age
Secondary percentage of time away from kindergarten or, for the parents, away from work 1 to 3 years of age
Secondary stratification of the above parameters according to bacterial colonisation of the airways 1 to 3 years of age
See also
  Status Clinical Trial Phase
Recruiting NCT05028153 - Azithromycin Treatment of Hospitalized Children With Asthmatic Symptoms Phase 2
Recruiting NCT06201156 - Comparison of Nebulizers vs Metered-Dose Inhalers With Spacer Device For Treatment Of Childhood Wheeze N/A